Earnings Call · Q3 2025 · Mgmt. Guidance
Updated 11-19-2025bearish
Transcript signals
Bull points
- We have thousands of patient testimonials supporting the effectiveness of the NexWave device. And it represents an amazing business opportunity. This is the main reason I came to Xynex.
Bear points
- Net revenue was $13.4 million compared to 50 million in the third quarter of 2024.
- The decline in net revenue for the three months ended September 30th, 2025 compared to the prior year period, are primarily related to the company's TRICARE payment suspension, along with a $2.8 million reduction in revenue related to payments received from TRICARE during the suspension period.
- Through the third quarter of 2025, changes to certain payers' claims submission and review practices have resulted in denials and payment delays, which has negatively impacted our revenue.
Read full transcript analysis ›